Investigational drug · Phase 3
adebelizumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Metastatic Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
12
Any phase or sponsor naming "adebelizumab"
First trial start
2025
Oct 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "adebelizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "adebelizumab" as an intervention, largest first.
- Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07170995 · 460 participants (planned) · Start Oct 22, 2025 · Primary completion Dec 2030
Drug: SHR-8068,adebelizumab and platinum-based chemotherapy; tislelizumab, and platinum-based chemotherapy · For: Advanced or Metastatic Non-small Cell Lung Cancer
Sites: Jinan, China
Nanjing Tianyinshan HospitalAcademic, hospital or other
NCT06893887 · 270 participants (planned) · Start May 22, 2025 · Primary completion Dec 15, 2027
Drug: FOLFOX4; Adebrelimab and 6 more · For: Hepatocellular Carcinoma(HCC)
Sites: Nanjing, China
- The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung CancerNot yet recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07704645 · 180 participants (planned) · Start Aug 2026 · Primary completion Jun 2028
Drug: Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection; Adebrelimab Injection combined with HRS-7058 Capsule · For: Resectable Non-small Cell Lung Cancer
Sites: Shanghai, China
Henan Cancer HospitalGovernment (non-federal)
NCT05769010 · 150 participants (planned) · Start Mar 31, 2023 · Primary completion Dec 30, 2028
Drug: SHR-A1811; Pyrotinib and 2 more · For: Metastatic Breast Cancer
Sites: Zhengzhou, China
- Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical TrialPivotal-lookingNot yet recruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT06771154 · 140 participants (planned) · Start Apr 1, 2025 · Primary completion Apr 1, 2029
Drug: Adebelimab Combined with Apatinib; Adebelimab · For: Recurrent/Metastatic Endometrial Cancer
Sites: Beijing, China, China
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT06768307 · 60 participants (planned) · Start Jan 7, 2025 · Primary completion Jan 31, 2027
Drug: First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC · For: SCLC, Extensive Stage; Immunotherapy; Chemotherapy and 1 more
Sites: Beijing, China
- Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder CancerActive, not recruiting
Harbin Medical UniversityAcademic, hospital or other
NCT07624201 · 58 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 1, 2028
Drug: Trastuzumab Rezetecan Combined with Adebelizumab · For: Muscle-Invasive Bladder Cancer (MIBC)
Sites: Harbin, China
Qianfoshan HospitalAcademic, hospital or other
NCT06125041 · 51 participants (planned) · Start Oct 30, 2023 · Primary completion Jul 31, 2026
Drug: Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy · For: Extensive Small Cell Lung Cancer
Sites: Jinan, China
- Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung CancerNot yet recruiting
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT07004712 · 46 participants (planned) · Start Jun 1, 2025 · Primary completion Mar 1, 2028
Drug: Adebelizumab combined with irinotecan liposome as second-line therapy · For: Small Cell Lung Cancer
Sites: Beijing, China
- Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal CancerNot yet recruiting
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT06599775 · 42 participants (planned) · Start Oct 2024 · Primary completion Oct 2026
Drug: Adebrelimab injection; Albumin-Bound Paclitaxel and 1 more · For: Resectable Esophageal Squamous Cell Carcinoma
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced or Metastatic Non-small Cell Lung Cancer
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
- IAP0971Phase 23 trials
SUNHO(China)BioPharmaceutical CO., Ltd. · Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.